Related Experiment Videos

Pleiotropic effects of ARB in metabolic syndrome

Satoru Yamada1

  • 1Diabetes Center, Kitasato Institute Hospital, 5-9-1 Shirokane, Minato-ku, Tokyo, Japan. yamada-s@insti.kitasato-u.ac.jp

Current Vascular Pharmacology
|December 15, 2010
PubMed

Insights

Angiotensin II receptor blockers (ARBs) show promise in treating metabolic syndrome by improving adiponectin levels, blood pressure, and fatty liver disease. PPARγ-activating ARBs may offer the most significant benefits for this condition.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Metabolic syndrome is a cluster of risk factors including abdominal obesity, dyslipidemia, hypertension, and insulin resistance.
  • These factors can manifest sequentially, termed the 'metabolic domino'.
  • The renin-angiotensin system (RAS) plays a role in this progression.

Purpose of the Study:

  • To describe the effects of angiotensin II receptor blockers (ARBs) on key metabolic syndrome components.
  • To explore the potential of ARBs in managing metabolic syndrome and its associated conditions.

Main Methods:

  • Review of clinical studies and research findings on ARB effects.
  • Analysis of ARB impact on adiponectin, blood pressure, and hepatic steatosis (fatty liver).

Main Results:

  • ARBs have been reported to elevate adiponectin levels.
  • ARB administration can prevent or regress hypertension.
  • ARBs may prevent triglyceride accumulation in the liver.
  • ARBs activating PPARγ appear more effective for these outcomes.

Conclusions:

  • PPARγ-activating ARBs present a hopeful therapeutic strategy for metabolic syndrome.
  • Further research is required to confirm the efficacy of PPARγ-activating ARBs in treating metabolic syndrome.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...